Safer drugs
better drugs
Safer drugs to treat autoimmune and inflammatory diseases in fragile patients.
Mission
Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who
may be already on multiple medications.
Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially
in children, and their families.
Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult
testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.
News & events
Oct 22, 2020
Initial outcome of Pediatric Alopecia Areata Ph II/III trial (RAAINBOW) published
August 19, 2020
Dr Kojima presents ALOBRCA (Chemotherapy Induced Alopecia trial) outcome at
JASCC 2020